NCT00545909 - BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis | Biotech Hunter

Enrollment

585

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

ibandronate [Bonviva/Boniva]

150mg po monthly for 6 months (+ feedback)

DRUG

ibandronate [Bonviva/Boniva]

150mg po monthly for 6 months (- feedback)

Trial Locations (57)

1000

Brussels

1020

Brussels

1021

Vienna

1040

Brussels

1060

Vienna

1100

Vienna

1130

Vienna

1150

Vienna

1160

Vienna

1180

Brussels

1200

Brussels

1420

Braine-l'Alleud

2018

Antwerp

2020

Antwerp

2170

Merksem

2180

Ekeren

2300

Turnhout

2311

Luxembourg

2610

Wilrijk

2763

Luxembourg

2800

Mechelen

3500

Hasselt

3600

Genk

4000

Liège

4020

Linz

Liège

4300

Waremme

4840

Vöcklabruck

5020

Salzburg

5100

Jambes

5500

Dinant

5530

Godinne

6000

Charleroi

6020

Innsbruck

6900

Bregenz

Aye

7000

Mons

7100

La Louvière

7500

Tournai

8000

Bruges

8036

Graz

8300

Knokke

8340

Sijsele

8400

Ostend

8500

Kortrijk

8800

Roeselare

9000

Ghent

9300

Aalst

10682

Athens

14561

Kifissia

16673

Athens

41110

Larissa

54636

Thessaloniki

55132

Thessaloniki

56429

Thessaloniki

Unknown

Gorey

Tipperary

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY